CRG PREMIERE Trademark

Trademark Overview


On Thursday, September 12, 2024, a trademark application was filed for CRG PREMIERE with the United States Patent and Trademark Office. The USPTO has given the CRG PREMIERE trademark a serial number of 98747364. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, March 19, 2025. This trademark is owned by CR Group L.P.. The CRG PREMIERE trademark is filed in the Insurance & Financial Services category with the following description:

Financial Services, namely, providing debt and equity financing to biopharmaceutical, biotechnology, healthcare, drug delivery, healthcare diagnostic, and medical device companies; Investment advisory services; Financial services, namely, providing structured financing for intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets; Financial services, namely, providing structured financing to ownership entities of intellectual property assets, namely, corporations, research institutions, and inventors; Financial investment in intellectual property assets, namely, the licensing of, and purchasing an ownership interest in, revenue streams from patents, trademarks, and trade secrets; Financial investment in assets protected by intellectual property, namely, the licensing of, and purchasing an ownership interest in, revenue-streams from intellectual property protected assets; Financial services, namely, the formation and management of pool investment ...
crg premiere

General Information


Serial Number98747364
Word MarkCRG PREMIERE
Filing DateThursday, September 12, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, March 19, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkCR GROUP PREMIERE
Goods and ServicesFinancial Services, namely, providing debt and equity financing to biopharmaceutical, biotechnology, healthcare, drug delivery, healthcare diagnostic, and medical device companies; Investment advisory services; Financial services, namely, providing structured financing for intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets; Financial services, namely, providing structured financing to ownership entities of intellectual property assets, namely, corporations, research institutions, and inventors; Financial investment in intellectual property assets, namely, the licensing of, and purchasing an ownership interest in, revenue streams from patents, trademarks, and trade secrets; Financial investment in assets protected by intellectual property, namely, the licensing of, and purchasing an ownership interest in, revenue-streams from intellectual property protected assets; Financial services, namely, the formation and management of pool investment vehicles and investment accounts for the purpose of investment in debt and equity interests in biopharmaceutical companies, biotechnology companies, healthcare companies, drug delivery companies, healthcare diagnostic companies, medical device companies, and intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets.

Classification Information


International Class036 - Insurance; financial affairs; monetary affairs; real estate affairs.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateThursday, September 12, 2024
Primary Code036
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCR Group L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressHouston, TX 77002

Trademark Events


Event DateEvent Description
Thursday, September 12, 2024NEW APPLICATION ENTERED
Monday, January 27, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 13, 2025ASSIGNED TO EXAMINER
Wednesday, March 19, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 19, 2025NON-FINAL ACTION WRITTEN
Wednesday, March 19, 2025NON-FINAL ACTION E-MAILED